Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 222

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

RAPAMYCIN PROTECTS ALLOGRAFTS FROM REJECTION WHILE SIMULTANEOUSLY ATTACKING TUMORS IN IMMUNOSUPPRESSED MICE

Koehl, Gudrun E., Andrassy, Joachim, Guba, Markus, Richter, Sebastian, Kroemer, Alexander, Scherer, Marcus N., Steinbauer, Markus, Graeb, Christian, Schlitt, Hans J., Jauch, Karl-Walter, Geissler, Edward K. · 2004 · Transplantation

Abstract

Cancer is an increasingly recognized problem associated with immunosuppression. Recent reports, however, suggest that the immunosuppressive agent rapamycin has anti-cancer properties that could address this problem. Thus far, rapamycin's effects on immunity and cancer have been studied separately. Here we tested the effects of rapamycin, versus cyclosporine A (CsA), on established tumors in mice simultaneously bearing a heart allograft. In one tumor-transplant model, BALB/c mice received subcutaneous syngenic CT26 colon adenocarcinoma cells 7 days before C3H ear-heart transplantation. Rapamycin or CsA treatment was initiated with transplantation. In a second model system, a B16 melanoma was established in C57BL/6 mice that received a primary vascularized C3H heart allograft. In vitro angiogenic effects of rapamycin and CsA were tested in an aortic ring assay. Results show that CT26 tumors grew for 2 weeks before tumor complications occurred. However, rapamycin protected allografts, inhibited tumor growth, and permitted animal survival. In contrast, CsA-treated mice succumbed to advancing tumors, albeit with a functioning allograft. Rapamycin's antitumor effect also functioned in severe combined immunodeficient BALB/c mice. Similar effects of the drugs occurred with B16 melanomas and primary vascularized C3H allografts in C57BL/6 mice. Furthermore, in this model, rapamycin inhibited the tumor growth-enhancing effects of CsA. Moreover, in vitro experiments showed that CsA promotes angiogenesis by a transforming growth factor-beta-related mechanism, and that this effect is abrogated by rapamycin. This study demonstrates that rapamycin simultaneously protects allografts from rejection and attacks tumors in a complex transplant-tumor situation. Notably, CsA protects allografts from rejection, but cancer progression is promoted in transplant recipients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00007890-200405150-00002

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 222

Metadata

Authors
Koehl, G. E., Andrassy, J., Guba, M., Richter, S., Kroemer, A., Scherer, M. N., Steinbauer, M., Graeb, C., Schlitt, H. J., Jauch, K.-W., & Geissler, E. K.
Venue
Transplantation
Published
2004-05
Volume
77
Issue
9
Pages
1319-1326
ISSN
0041-1337 (ISSN-L)
OpenAlex
W2059257410
Cited by
222
References
2
FWCI
6.23
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RAPAMYCIN PROTECTS ALLOGRAFTS FROM REJECTION WHILE SIMULTANEOUSLY ATTACKING TUMORS IN IMMUNOSUPPRESSED MICE. https://app.cochat.ai/papers/10.1097/00007890-200405150-00002
The paper
Koehl, G. E., Andrassy, J., Guba, M., Richter, S., Kroemer, A., Scherer, M. N., Steinbauer, M., Graeb, C., Schlitt, H. J., Jauch, K.-W., & Geissler, E. K. (2004). RAPAMYCIN PROTECTS ALLOGRAFTS FROM REJECTION WHILE SIMULTANEOUSLY ATTACKING TUMORS IN IMMUNOSUPPRESSED MICE. Transplantation. https://doi.org/10.1097/00007890-200405150-00002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.